Iron Status and Hypoxic Pulmonary Vascular Responses

Pulmonary Arterial Hypertension Clinical Trial

Official title:

Effect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by Intravenous Iron

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01847352
• Other study ID #: 12/SC/0710
• Status: Completed
• Phase: N/A
• First received: May 1, 2013
• Last updated: May 5, 2016
• Start date: February 2013
• Est. completion date: April 2014

Study information

• Verified date: May 2016
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

On exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (PASP, blood pressure through the lungs) to increase. We have previously shown that raising iron by giving an infusion of iron into a vein reduces this pressure rise and that lowering iron by giving a drug that binds iron, magnifies this response. This is potentially a clinically important observation since iron-deficient people may be at increased risk of pulmonary hypertension if exposed transiently or permanently to hypoxia due to lung disease or residence at high altitude; furthermore if this were true then intravenous iron could be an important treatment in this patient group in the event of hypoxic exposure. The observed effects of iron on PASP are likely to be because iron levels affect oxygen sensing. Low iron levels make the body behave as if exposed to low oxygen by inhibiting the breakdown of the family of oxygen-sensing transcription factors, 'hypoxia inducible factor' or HIF. This includes one of the body's normal responses to low oxygen levels - raising blood pressure through the lungs.

This study will answer the question (1) do iron-deficient volunteers have a greater rise in PASP with hypoxia than those who are iron-replete, and (2) does giving intravenous iron cause a greater reduction in the rise in PASP in those who are iron-deficient than iron-replete? The purpose of this study is not to test the safety or clinical efficacy of iron which is already known.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing and able to give informed consent for participation in the study

• Men and women aged 18 years or older and generally in good health

• Detectable tricuspid regurgitation on echocardiography during both normoxia and hypoxia enabling measurement of pulmonary arterial pressure

• For iron-deficient volunteers: ferritin =15microg/L and transferrin saturation <16%

• For iron-replete volunteers: ferritin =20microg/L and transferrin saturation =20%

Exclusion Criteria:

• Haemoglobin <8.0g/dl

• Haemoglobinopathy

• Iron overload defined as ferritin >300microg/L

• Hypoxia at rest or on walking (SaO2 <94%) or significant comorbidity that may affect haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension, uncontrolled asthma or chronic obstructive pulmonary disease

• Exposure to high altitude (>2,500m) within the previous six weeks or air travel >4 hours within the previous week

• Iron supplementation or blood transfusion within the previous 6 weeks

• Pregnancy or breast feeding

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Hypertension
• Iron Deficiency
• Lung Hypoxia
• Pulmonary Arterial Hypertension

Intervention

Drug:
• Intravenous administration of ferric carboxymaltose
Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg

Other:
• Subacute hypoxic exposures
Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion

Locations

Country	Name	City	State
United Kingdom	University of Oxford Department of Physiology, Anatomy and Genetics	Oxford	Oxfordshire

Sponsors (3)

Lead Sponsor	Collaborator
University of Oxford	British Heart Foundation, National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

References & Publications (5)

Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol (1985). 2002 Jun;92(6):2501-7. — View Citation

Frise MC, Cheng HY, Nickol AH, Curtis MK, Pollard KA, Roberts DJ, Ratcliffe PJ, Dorrington KL, Robbins PA. Clinical iron deficiency disturbs normal human responses to hypoxia. J Clin Invest. 2016 May 3. pii: 85715. doi: 10.1172/JCI85715. [Epub ahead of pr — View Citation

Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008 Dec 15;586(24):5999-6005. doi: 10.1113/jphysiol.2008.160960. Epub 2008 Oct 27. — View Citation

Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, León-Velarde F, Robbins PA. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009 Oct 7;302(13):1444-50. doi: 10.1001/jama.2009.1404. — View Citation

Talbot NP, Smith TG, Privat C, Nickol AH, Rivera-Ch M, León-Velarde F, Dorrington KL, Robbins PA. Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial. High Alt Med Biol. 2011 Fall;12(3):265-9. doi: 10.1089/ham.2011.1005. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Fatigue scores in iron-replete versus iron-deficient volunteers		Assessed at baseline visit	No
Primary	?PASP in iron-replete compared to iron-deficient volunteers	Difference between the rise in pulmonary artery systolic pressure during a hypoxic challenge in iron-replete compared to iron-deficient volunteers	During six hours of hypoxia without prior iron infusion	No
Secondary	?PASP, with versus without prior iron infusion, in iron-replete compared to iron-deficient volunteers	Difference between the rise in pulmonary artery systolic pressure during a hypoxic challenge in iron-replete compared to iron-deficient volunteers, with versus without a prior iron infusion	During two six-hour periods of hypoxia; assessments separated by at least a week	No
Secondary	Blood parameter changes, pre- versus post-intravenous iron, in iron-replete compared to iron-deficient volunteers		After six hours of hypoxia, at both study assessments	No
Secondary	Ventilation parameter changes, pre- versus post-intravenous iron, in iron-replete compared to iron-deficient volunteers		During six hours of hypoxia, at both study assessments	No

External Links

•   Funding Body Website
•   Funding Body Website
•   Research Group Website